SMAD3 and Parkinson disease: Particularly, Smad3 deficiency has been found to significantly affect the dopaminergic system in animal models, potentially contributing to the early stages of Parkinsonism through the induced catabolism of dopamine, decreased trophic and astrocytic support, and the potential induction of α-synuclein aggregation [290].